Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effects of two types of abutmentspre-fabricated standardized titanium and customized anatomical zirconiaon the health of tissues around single implant-supported posterior teeth. This randomized controlled clinical trial focuses on how these abutments impact implant biocompatibility, peri-implant tissue stability, bone loss seen on X-rays, and the quality of life related to oral health. The study builds upon a previous phase where participants had tooth extractions, alveolar preservation, and implant placement with a six-month healing period. Participants who have successfully integrated implants will be randomly assigned to receive prosthetic rehabilitation with either titanium abutments or zirconia abutments, both supporting single zirconia crowns in back teeth. The prosthetic and lab procedures follow standardized digital protocols. The study includes follow-up visits at prosthesis delivery and 1, 3, 6, and 12 months afterward to monitor changes and responses. During the study, researchers will collect samples of peri-implant crevicular fluid and biofilm for biomolecular analysis and measure periodontal health, mucosa thickness, and bone levels using standardized X-rays. Digital scans will assess soft tissue volume and stability. The main outcome is microbial colonization at the implant sites over 12 months. Secondary outcomes include demographic data, clinical parameters, bone level changes, and soft tissue stability. This research aims to improve understanding of how abutment materials influence long-term implant health.